| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
12,227 |
11,198 |
$674K |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
6,059 |
5,726 |
$512K |
| 99392 |
Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) |
2,192 |
2,106 |
$163K |
| 99393 |
Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) |
1,536 |
1,488 |
$114K |
| 99391 |
Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) |
1,763 |
1,445 |
$113K |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
2,667 |
2,597 |
$80K |
| 92552 |
|
2,047 |
1,995 |
$55K |
| 90688 |
|
3,760 |
3,579 |
$44K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
2,377 |
1,129 |
$30K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
2,151 |
2,089 |
$28K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
923 |
778 |
$28K |
| 99394 |
Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) |
314 |
301 |
$25K |
| 99000 |
|
10,324 |
9,474 |
$21K |
| 87430 |
|
1,633 |
1,529 |
$20K |
| 90700 |
|
1,679 |
1,578 |
$20K |
| 90670 |
|
809 |
746 |
$19K |
| 96127 |
|
4,593 |
4,234 |
$18K |
| G2211 |
Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established) |
1,978 |
1,876 |
$14K |
| 90713 |
|
919 |
851 |
$11K |
| 90648 |
|
853 |
791 |
$9K |
| 0001A |
|
194 |
191 |
$8K |
| 90686 |
|
527 |
519 |
$7K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
822 |
782 |
$6K |
| 0071A |
|
139 |
137 |
$6K |
| 0002A |
|
133 |
129 |
$5K |
| 96110 |
Developmental screening, with scoring and documentation, per standardized instrument |
555 |
534 |
$4K |
| 90658 |
|
335 |
335 |
$4K |
| 90651 |
|
106 |
106 |
$4K |
| 0072A |
|
94 |
94 |
$4K |
| 99173 |
|
1,453 |
1,403 |
$3K |
| 90685 |
|
219 |
216 |
$2K |
| G0444 |
Annual depression screening, 5 to 15 minutes |
270 |
264 |
$2K |
| 0124A |
|
65 |
64 |
$2K |
| 99070 |
|
1,024 |
871 |
$2K |
| 99441 |
|
122 |
88 |
$2K |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
112 |
103 |
$2K |
| 81002 |
|
588 |
559 |
$2K |
| 96161 |
|
573 |
477 |
$1K |
| 0004A |
|
33 |
32 |
$1K |
| 36416 |
|
2,904 |
2,581 |
$1K |
| 90460 |
Immunization administration through 18 years of age via any route, first or only component |
84 |
75 |
$1K |
| 90633 |
|
72 |
68 |
$906.80 |
| G8510 |
Screening for depression is documented as negative, a follow-up plan is not required |
117 |
117 |
$840.00 |
| 90677 |
|
13 |
13 |
$805.67 |
| 90680 |
|
59 |
56 |
$692.13 |
| 90619 |
|
15 |
15 |
$552.36 |
| 91320 |
|
15 |
12 |
$421.66 |
| 0081A |
|
14 |
14 |
$376.00 |
| 99050 |
|
37 |
36 |
$337.53 |
| 0082A |
|
14 |
13 |
$236.00 |
| 90715 |
|
13 |
13 |
$213.60 |
| 90744 |
|
16 |
13 |
$192.08 |
| 36415 |
Collection of venous blood by venipuncture |
58 |
57 |
$159.45 |
| 99177 |
|
36 |
36 |
$149.56 |
| 94760 |
|
81 |
73 |
$108.28 |
| 99174 |
|
15 |
12 |
$67.60 |
| J7611 |
Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, concentrated form, 1 mg |
112 |
103 |
$19.63 |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
12 |
12 |
$0.00 |